4D Molecular Therapeutics appoints Noriyuki Kasahara to Board, promotes Fred Kamal to President and COO

4D Molecular Therapeutics, Inc.

Appointed Noriyuki Kasahara, M.D., Ph.D., to Board as Class I director and Chair of Science and Technology Committee.
Promoted Fred Kamal, Ph.D., to President and COO; base salary increased to $475,000, annual target bonus 45%.
Granted Kasahara option for 45,000 shares at $8.06; Kamal granted option for 15,000 shares at $8.06.
Kasahara is Professor at UCSF with 30+ years in gene therapy, author of 150+ articles, inventor on 18 patents.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Fred Kamal

President and Chief Operating Officer

FDMT · 4D Molecular Therapeutics, Inc.

Effective: 2022-09-23
Filed: September 27, 2022, 7:59 PM ET

appointed Fred Kamal, Ph.D., the Company’s current Chief Operating Officer and Chief Technical Officer, as President and Chief Operating Officer of the Company

Appointed

Noriyuki Kasahara

Class I director

FDMT · 4D Molecular Therapeutics, Inc.

Effective: 2022-09-23
Filed: September 27, 2022, 7:59 PM ET

appointed Noriyuki Kasahara, M.D., Ph.D., to the Board as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fred Kamal changed role as President and Chief Operating Officer at 4D Molecular Therapeutics, Inc..

Action: promoted
Role: President and Chief Operating Officer

Exact text from the filing

appointed Fred Kamal, Ph.D., the Company’s current Chief Operating Officer and Chief Technical Officer, as President and Chief Operating Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Noriyuki Kasahara was appointed as Class I director at 4D Molecular Therapeutics, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

appointed Noriyuki Kasahara, M.D., Ph.D., to the Board as a Class I director

View on SEC.gov

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-252180

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.